Journal of Bone Oncology最新文献

{"title":"The survival and complication profiles of the Compress® Endoprosthesis: A systematic review and meta-analysis","authors":"Haolong Li ,&nbsp;Xinxin Zhang ,&nbsp;Xinyu Li ,&nbsp;Jingnan Shen ,&nbsp;Junqiang Yin ,&nbsp;Changye Zou ,&nbsp;Xianbiao Xie ,&nbsp;Gang Huang ,&nbsp;Tiao Lin","doi":"10.1016/j.jbo.2024.100623","DOIUrl":"10.1016/j.jbo.2024.100623","url":null,"abstract":"<div><h3>Background/purpose</h3><p>This study aimed to summarize the survival and complication profiles of the compress® endoprosthesis (CPS) through a systematic review and <em>meta</em>-analysis.</p></div><div><h3>Methods</h3><p>Online databases (PubMed, EMBASE and Web of Science) were searched from inception to November 2023. Trials were included that involved the use of CPS for endoprosthetic replacement in patients with massive segmental bone defects. Patients’ clinical characteristics<!--> <!-->and demographic data were extracted using a standardized form. The methodological quality of included 13 non-comparative studies was assessed on basis of the Methodological Index for Non-Randomized Studies (MINORS). All the available Kaplan-Meier curves in the included studies were digitized and combined using Engauge-Digitizer software and the R Project for Statistical Computing.</p></div><div><h3>Results</h3><p>The <em>meta</em>-analysis of thirteen included studies indicated: the all-cause failure rates of CPS were 26.3 % after surgery, in which the occurrence rates of aseptic loosening were 5.8 %. And the incidences of other complications were as follows: soft tissue failure (1.8 %), structure failure (8.2 %), infection (9.5 %), tumor progression (1.1 %). The 1-, 4-, and 8-year overall survival rates for all-cause failure with 95 % CI were 89 % (86 %-92 %), 75 % (71 %-79 %) and 65 % (60 %-70 %), respectively. The estimated mean survival time of all-cause failure was 145 months (95 % CI, 127–148 months), and the estimated median survival time of all-cause failure was 187 months (95 % CI, 135–198 months). The 1-, 4-, and 8-year overall survival rates of aseptic loosening with 95 % CI were 96 % (94 %-98 %), 91 % (87 %-95 %) and 88 % (83 %-93 %), respectively. The estimated mean survival time of aseptic loosening was 148 months (95 % CI, 137–153 months).</p></div><div><h3>Conclusion</h3><p>CPS’s innovative spring system promotes bone ingrowth by providing immediate and high-compression fixation, thereby reducing the risk of aseptic loosening caused by stress shielding and particle-induced osteolysis. CPS requires less residual bone mass for reconstructing massive segmental bone defects and facilitates easier revision due to its non-cemented fixation. In addition, the survival rate, estimated mean survival time, and complication rates of CPS are not inferior to those of common endoprosthesis.</p></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"47 ","pages":"Article 100623"},"PeriodicalIF":3.4,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212137424001039/pdfft?md5=fa1880d0e1d725a2c57807cb9e74369c&pid=1-s2.0-S2212137424001039-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141711140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive diagnostic model for osteosarcoma classification using CT imaging features","authors":"Yiran Wang ,&nbsp;Zhixiang Wang ,&nbsp;Bin Zhang ,&nbsp;Fan Yang","doi":"10.1016/j.jbo.2024.100622","DOIUrl":"https://doi.org/10.1016/j.jbo.2024.100622","url":null,"abstract":"<div><h3>Objective</h3><p>The main objective of this study was to create and assess a detailed diagnostic model with an optimizing feature selection algorithm that combines computed tomography (CT) imaging characteristics, demographic information, and genetic markers to enhance the accuracy of benign and malignant classification of osteosarcoma. This research seeks to enhance the early identification and categorization of benign and malignant of osteosarcoma, ultimately enabling more personalized and efficient treatment approaches.</p></div><div><h3>Methods</h3><p>Data from 225 patients diagnosed with osteosarcoma at two different medical institutions between June 2018 and June 2021 were gathered for this research study. A novel feature selection approach that combined Principal Component Analysis (PCA) with Improved Particle Swarm Optimization (IPSO) was utilized to analyze 1743 image-derived features. The performance of the resulting model was evaluated using metrics such as area under the receiver operating characteristic curve (AUC), accuracy (ACC), sensitivity (SEN), and specificity (SPE), and compared to models developed using conventional feature selection methods.</p></div><div><h3>Results</h3><p>The proposed model showed promising predictive performance with an AUC of 0.87, accuracy of 0.80, sensitivity of 0.75, and specificity of 0.85. These results suggest improved predictive ability compared to models built using traditional feature selection techniques, particularly in terms of accuracy and specificity. However, there is room for improvement in enhancing sensitivity.</p></div><div><h3>Conclusion</h3><p>Our study introduces a novel predictive model for distinguishing between benign and malignant osteosarcoma., emphasizing its potential significance in clinical practice. Through the utilization of CT imaging features, our model shows improved accuracy and specificity, marking progress in the early detection and classification of osteosarcoma as either benign or malignant. Future investigations will concentrate on enhancing the model’s sensitivity and validating its effectiveness on a larger dataset, aiming to boost its clinical relevance and support personalized treatment approaches for osteosarcoma.</p></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"47 ","pages":"Article 100622"},"PeriodicalIF":3.4,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212137424001027/pdfft?md5=e6268d6b2ac90627843a1516f401e11a&pid=1-s2.0-S2212137424001027-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141607329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world experiences in patients with Ewing sarcoma treated at a specialist centre in Turkey","authors":"Selma Çakmakcı ,&nbsp;Neriman Sarı ,&nbsp;Ebru Atasever Akkaş ,&nbsp;Fatih Yıldız ,&nbsp;Ebru Karakaya ,&nbsp;Bektaş Kaya ,&nbsp;Bedii Şafak Güngör ,&nbsp;Ömür Berna Çakmak Öksüzoğlu ,&nbsp;İnci Ergürhan İlhan","doi":"10.1016/j.jbo.2024.100619","DOIUrl":"https://doi.org/10.1016/j.jbo.2024.100619","url":null,"abstract":"<div><h3>Objectives</h3><p>The present study evaluates the clinical outcomes of children, adolescents and adults with Ewing sarcoma and identifies the prognostic factors.</p></div><div><h3>Methods</h3><p>Included in the study were 222 pediatric and adult patients diagnosed with Ewing sarcoma (EwS) who were followed up between 1992 and 2019, and whose data were analyzed retrospectively.</p></div><div><h3>Results</h3><p>The median age of 131 male and 91 female patients included in the study was 13 (1–64). The median follow-up duration of the survivors was 79 months (range, 11–182 months). The 3-year EFS rate of the 222 patients was 34 % (Confidence Interval (CI) (0.158–0.242 %) and the OS rate was 54 % (CI, 0.289–0.590 %). For the non-metastatic patients, the 3-year EFS rate was 47 % and the OS was 68 %, while for the metastatic patients the 3-year EFS rate was 13 % and the OS was 30 %. Of the patient sample, 81 (36, 5 %) survived, of whom 72 were continuously free of disease while the disease persisted in nine, and three developed a secondary neoplasm (2 of whom subsequently died while one survived disease-free). Of the 129 patients who relapsed with metastases and/or local recurrence, eight survived and are disease-free, nine are alive with uncontrolled disease; five were lost to follow-up and 107 died.</p></div><div><h3>Conclusion</h3><p>The findings of the present study suggest metastatic disease at presentation and positive margins after surgery to be of prognostic significance in EwS. Disruptions in aggressive local treatments may reduce the chances of cure in EwS.</p></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"47 ","pages":"Article 100619"},"PeriodicalIF":3.4,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221213742400099X/pdfft?md5=483985fe57369390067afb74737965d1&pid=1-s2.0-S221213742400099X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141607330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Senescence in the bone marrow microenvironment: A driver in development of therapy-related myeloid neoplasms","authors":"Angelo Jose Guilatco ,&nbsp;Mithun Vinod Shah ,&nbsp;Megan Moore Weivoda","doi":"10.1016/j.jbo.2024.100620","DOIUrl":"https://doi.org/10.1016/j.jbo.2024.100620","url":null,"abstract":"<div><p>Therapy-related myeloid neoplasms (t-MN) are a growing concern due to the continued use of cytotoxic therapies to treat malignancies. Cytotoxic therapies have been shown to drive therapy-induced senescence in normal tissues, including in the bone marrow microenvironment (BMME), which plays a crucial role in supporting normal hematopoiesis. This review examines recent work that focuses on the contribution of BMME senescence to t-MN pathogenesis, as well as offers a perspective on potential opportunities for therapeutic intervention.</p></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"47 ","pages":"Article 100620"},"PeriodicalIF":3.4,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212137424001003/pdfft?md5=9b286f878ffa9d784caa6b6c9fac5f32&pid=1-s2.0-S2212137424001003-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141593628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mometasone furoate inhibits tumor progression and promotes apoptosis through activation of the AMPK/mTOR signaling pathway in osteosarcoma","authors":"Zhaohui Li ,&nbsp;Xiang Fei ,&nbsp;Zhen Pan ,&nbsp;Yonghui Liang ,&nbsp;Qingcheng Yang ,&nbsp;Dongdong Cheng","doi":"10.1016/j.jbo.2024.100618","DOIUrl":"https://doi.org/10.1016/j.jbo.2024.100618","url":null,"abstract":"<div><p>Osteosarcoma is the most common primary malignant bone tumor in adolescents. While treatments for osteosarcoma have improved, the overall survival has not changed for three decades, and thus, new targets for therapeutic development are needed. Recently, glucocorticoids have been reported to have antitumor effects. Mometasone furoate (MF), a synthetic glucocorticoid, is of great value in clinical application, but there are few reports on its antitumor effect. Here, we verified the effect of MF on osteosarcoma <em>in vitro</em> and <em>in vivo</em>. <em>In vitro</em>, cell proliferation, cell cycle progression, apoptosis and cell metastasis were detected using Cell Counting Kit-8 (CCK-8), colony formation, flow cytometry, wound-healing and transwell assays, respectively<em>. In vivo</em>, we generated a xenograft mouse model. To examine the potential role of the AMPK pathway, an AMPK-specific inhibitor (dorsomorphin) was used. The expression levels of factors related to the cell cycle, apoptosis and activation of the AMPK/mTOR pathway were assessed by immunohistochemistry and Western blotting. MF inhibited proliferation and metastasis and induced S phase arrest and apoptosis in osteosarcoma cells in a dose-dependent manner. <em>In vivo</em>, MF effectively inhibited osteosarcoma cell growth and pulmonary metastasis; however, it had no negative effect on the internal organs. Additionally, MF could activate the AMPK/mTOR pathway in osteosarcoma. Dorsomorphin significantly attenuated MF-induced antitumor activities. In summary, MF can inhibit osteosarcoma proliferation and metastasis and promote osteosarcoma cell apoptosis through the AMPK/mTOR signaling pathway <em>in vitro</em> and <em>in vivo</em>, which can provide a new rationale for subsequent academic and clinical research on osteosarcoma treatment.</p></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"47 ","pages":"Article 100618"},"PeriodicalIF":3.4,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212137424000988/pdfft?md5=053589ba6cad63a6290788b17e441a8e&pid=1-s2.0-S2212137424000988-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141479150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of quantitative CT texture analysis on the outcome of CT-guided bone biopsy","authors":"Silvio Wermelskirchen ,&nbsp;Jakob Leonhardi ,&nbsp;Anne-Kathrin Höhn ,&nbsp;Georg Osterhoff ,&nbsp;Nikolas Schopow ,&nbsp;Silke Zimmermann ,&nbsp;Sebastian Ebel ,&nbsp;Gordian Prasse ,&nbsp;Jeanette Henkelmann ,&nbsp;Timm Denecke ,&nbsp;Hans-Jonas Meyer","doi":"10.1016/j.jbo.2024.100616","DOIUrl":"https://doi.org/10.1016/j.jbo.2024.100616","url":null,"abstract":"<div><p>Texture analysis can provide new imaging-based biomarkers. Texture analysis derived from computed tomography (CT) might be able to better characterize patients undergoing CT-guided percutaneous bone biopsy. The present study evaluated this and correlated texture features with bioptic outcome in patients undergoing CT-guided bone biopsy. Overall, 123 patients (89 female patients, 72.4 %) were included into the present study. All patients underwent CT-guided percutaneous bone biopsy with an 11 Gauge coaxial needle. Clinical parameters and quantitative imaging features were investigated. Random forest classifier was used to predict a positive biopsy result. Overall, 69 patients had osteolytic metastasis (56.1 %) and 54 had osteoblastic metastasis (43.9 %). The overall positive biopsy rate was 72 %. The developed radiomics model demonstrated a prediction accuracy of a positive biopsy result with an AUC of 0.75 [95 %CI 0.65 – 0.85]. In a subgroup of breast cancer patients, the model achieved an AUC of 0.85 [95 %CI 0.73 – 0.96]. In the subgroup of non-breast cancer patients, the signature achieved an AUC of 0.80 [95 %CI 0.60 – 0.99]. Quantitative CT imaging findings comprised of conventional and texture features can aid to predict the bioptic result of CT-guided bone biopsies. The developed radiomics signature aids in clinical decision-making, and could identify patients at risk for a negative biopsy.</p></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"47 ","pages":"Article 100616"},"PeriodicalIF":3.4,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212137424000964/pdfft?md5=293625d54b9f75bc47fd2bff42864547&pid=1-s2.0-S2212137424000964-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141444328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of androgen deprivation therapy on bone microarchitecture in men with prostate cancer: A longitudinal observational study (The ANTELOPE Study)","authors":"Catherine Handforth ,&nbsp;Margaret A. Paggiosi ,&nbsp;Richard Jacques ,&nbsp;Fatma Gossiel ,&nbsp;Richard Eastell ,&nbsp;Jennifer S. Walsh ,&nbsp;Janet E. Brown","doi":"10.1016/j.jbo.2024.100611","DOIUrl":"https://doi.org/10.1016/j.jbo.2024.100611","url":null,"abstract":"<div><h3>Introduction</h3><p>Androgen Deprivation Therapy (ADT) for prostate cancer (PC) has substantial negative impacts on the musculoskeletal system and body composition. Many studies have focused on the effects of ADT on areal bone mineral density (aBMD), but aBMD does not capture key determinants of bone strength and fracture risk, for example volumetric bone density (vBMD), geometry, cortical thickness and porosity, trabecular parameters and rate of remodelling. More specialist imaging techniques such as high-resolution peripheral quantitative computed tomography (HR-pQCT) have become available to evaluate these parameters. Although it has previously been demonstrated that bone microarchitectural deterioration occurs in men undergoing ADT, the aim of the ANTELOPE study was to examine longitudinal changes in bone microstructure alongside a range of musculoskeletal parameters and frailty, comparing men with PC receiving ADT alone or ADT plus chemotherapy for metastatic disease, with a healthy age-matched population.</p></div><div><h3>Methods</h3><p>We used HR-pQCT to investigate effects of 12 months of ADT on vBMD and microstructural parameters, complemented by assessment of changes in aBMD, serum bone turnover markers, sex hormones, body composition, grip strength, physical and muscle function, frailty and fracture risk. We studied three groups: Group A − men with localised/locally advanced PC due to commence ADT; Group B − men with newly diagnosed hormone-sensitive, metastatic PC, starting ADT alongside docetaxel chemotherapy and steroids; Group C − healthy, age-matched men. The primary endpoint was change in vBMD (Group A vs Group C) at the distal radius.</p></div><div><h3>Results</h3><p>Ninety-nine participants underwent baseline study assessments (Group A: n = 38, Group B: n = 30 and Group C: n = 31). Seventy-five participants completed all study assessments (Group A (29), Group B (18), Group C (28). At baseline, there were no significant differences between Groups A and C in any of the BMD or bone microstructure outcomes of interest. After 12 months of ADT treatment, there was a significantly greater decrease in vBMD (p &lt; 0.001) in Group A (mean 12-month change = -13.7 mg HA/cm³, −4.1 %) compared to Group C (mean 12-month change = -1.3 mg HA/cm³, −0.4 %), demonstrating achievement of primary outcome. Similar effects were observed when comparing the change in vBMD between Group B (mean 12-month change = -13.5 mg HA/cm³, −4.3 %) and Group C. These changes were mirrored in aBMD. ADT resulted in microstructural deterioration, a reduction in estimated bone strength and an increase in bone turnover. There was evidence of increase in total fat mass and trunkal fat mass in ADT-treated patients, with marked loss in upper limb mass, along with BMI gain. Frailty increased and physical performance and strength deteriorated in both ADT groups, relative to the healthy control group.</p></div><div><h3>Conclusion</h3","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"47 ","pages":"Article 100611"},"PeriodicalIF":3.4,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212137424000915/pdfft?md5=8c26eef81ce7350557725b3defcad435&pid=1-s2.0-S2212137424000915-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141439129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous vertebroplasty/kyphoplasty contributes to the improved outcome in patients with newly diagnosed multiple myeloma: A single center cohort study","authors":"Fujing Zhang ,&nbsp;Shuzhong Liu ,&nbsp;Xi Zhou ,&nbsp;Wei Wang ,&nbsp;Congwei Jia ,&nbsp;Qin Wang ,&nbsp;Yong Liu ,&nbsp;Junling Zhuang","doi":"10.1016/j.jbo.2024.100615","DOIUrl":"10.1016/j.jbo.2024.100615","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate the efficacy and prognosis of percutaneous vertebroplasty/kyphoplasty (PVP/PKP) in patients with newly diagnosed multiple myeloma (NDMM).</p></div><div><h3>Methods</h3><p>Clinical data of NDMM patients who underwent PVP/PKP during front-line regimen at Peking Union Medical College Hospital from January 1, 2003, to June 30, 2023, were analyzed. Patients with comparable bone diseases not receiving orthopedic surgery were selected as controls. Visual analogue scale (VAS) score, progression-free survival (PFS), and overall survival (OS) were compared.</p></div><div><h3>Results</h3><p>Baseline characteristics were matched between the surgical group (n = 51 with 56 surgeries) and non-surgical group (n = 102), including demographics, tumor load, International Staging System (ISS), bone diseases, cytogenetic abnormalities, first-line treatment, and autologous stem-cell transplantation (ASCT). Bone lesions for PVP/PKP were located at thoracic vertebrae (53.6 %, 30/56) or lumbosacral vertebrae (46.4 %, 26/56). The postoperative VAS score was significantly improved (2.25 ± 0.81 vs 5.92 ± 1.05, <em>P</em> &lt; 0.001). The median follow-up time was 51[38–70] months. Kaplan-Meier survival analysis suggested that both PFS (37[17–89] vs 23[12–61] months, HR 0.648, 95 %CI 0.431–0.973, <em>P</em> = 0.047) and OS (not reached vs 66[28-NR] months, HR 0.519, 95 %CI 0.296–0.910, <em>P</em> = 0.045) were significantly prolonged in the surgical group. COX multivariate analysis suggested that PVP/PKP was an independent prognostic factor for PFS (<em>P</em> = 0.021, HR 0.589, 95 %CI 0.376–0.922) and OS (<em>P</em> = 0.038, HR 0.496, 95 %CI 0.255–0.963). Subgroup analysis confirmed that patients with ISS II/III or non-ASCT achieved better PFS and OS in the surgical group (PFS: <em>P</em> = 0.033, <em>P</em> = 0.040; OS: <em>P</em> = 0.024, <em>P</em> = 0.018 respectively), while similar survival outcome was observed in patients with ISS I or ASCT between two groups.</p></div><div><h3>Conclusion</h3><p>For NDMM patients, not only does PVP/PKP alleviate bone pain, meanwhile, it improves the PFS and OS in advanced subpopulation or non-transplant myeloma patients, which suggests that shortening the gap from symptom onset to diagnosis by orthopedic surgery favors clinical prognosis.</p></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"47 ","pages":"Article 100615"},"PeriodicalIF":3.4,"publicationDate":"2024-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212137424000952/pdfft?md5=44310225ff38c71d787f34a45721389f&pid=1-s2.0-S2212137424000952-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141398205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiomic nomogram for predicting high-risk cytogenetic status in multiple myeloma based on fat-suppressed T2-weighted magnetic resonance imaging","authors":"Suwei Liu ,&nbsp;Haojie Pan ,&nbsp;Shenglin Li ,&nbsp;Zhengxiao Li ,&nbsp;Jiachen Sun ,&nbsp;Tiezhu Ren ,&nbsp;Junlin Zhou","doi":"10.1016/j.jbo.2024.100617","DOIUrl":"10.1016/j.jbo.2024.100617","url":null,"abstract":"<div><h3>Rationale and Objectives</h3><p>Radiomics has demonstrated potential in predicting the cytogenetic status of multiple myeloma (MM). However, the role of single-sequence radiomic nomograms in predicting the high-risk cytogenetic (HRC) status of MM remains underexplored. This study aims to develop and validate radiomic nomograms based on fat-suppressed T2-weighted images (T2WI-FS) for predicting MM’s HRC status, facilitating pre-treatment decision-making and prognostic assessment.</p></div><div><h3>Materials and methods</h3><p>A cohort of 159 MM patients was included, comprising 71 HRC and 88 non-HRC cases. Regions of interest within the most significant tumor lesions on T2WI-FS images were manually delineated, yielding 1688 features. Fourteen radiomic features were selected using 10-fold cross-validation, employing methods such as variance thresholds, Student’s <em>t</em>-test, redundancy analysis, and least absolute shrinkage and selection operator (LASSO). Logistic regression was utilized to develop three prediction models: a clinical model (model 1), a T2WI-FS radiomic model (model 2), and a combined clinical-radiomic model (model 3). Receiver operating characteristic (ROC) curves evaluated and compared the diagnostic performance of these models. Kaplan-Meier survival analysis and log-rank tests assessed the prognostic value of the radiomic nomograms.</p></div><div><h3>Results</h3><p>Models 2 and 3 demonstrated significantly greater diagnostic efficacy compared to model 1 (<em>p</em> &lt; 0.05). The areas under the ROC curve for models 1, 2, and 3 were as follows: training set—0.650, 0.832, and 0.846; validation set—0.702, 0.730, and 0.757, respectively. Kaplan-Meier survival analysis indicated comparable prognostic values between the radiomic nomogram and MM cytogenetic status, with log-rank test results (<em>p</em> &lt; 0.05) and concordance indices of 0.651 and 0.659, respectively; z-score test results were not statistically significant (<em>p</em> = 0.153). Additionally, Kaplan-Meier analysis revealed that patients in the non-HRC group, low-RS group, and aged ≤ 60 years exhibited the longest overall survival, while those in the HRC group, high-RS group, and aged &gt; 60 years demonstrated the shortest overall survival (<em>p</em> = 0.004, Log-rank test).</p></div><div><h3>Conclusions</h3><p>Radiomic nomograms are capable of predicting the HRC status in MM. The cytogenetic status, radiomics model Rad score, and age collectively influence the overall survival of MM patients. These factors potentially contribute to pre-treatment clinical decision-making and prognostic assessment.</p></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"47 ","pages":"Article 100617"},"PeriodicalIF":3.4,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212137424000976/pdfft?md5=4c6f93c766a290f1194b28aa9b193d20&pid=1-s2.0-S2212137424000976-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141390134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative prediction of high-grade osteosarcoma response to neoadjuvant therapy based on a plain CT radiomics model: A dual-center study","authors":"Fan Yang ,&nbsp;Ying Feng ,&nbsp;Pengfei Sun ,&nbsp;Alberto Traverso ,&nbsp;Andre Dekker ,&nbsp;Bin Zhang ,&nbsp;Zhen Huang ,&nbsp;Zhixiang Wang ,&nbsp;Dong Yan","doi":"10.1016/j.jbo.2024.100614","DOIUrl":"https://doi.org/10.1016/j.jbo.2024.100614","url":null,"abstract":"<div><h3>Objective</h3><p>To develop a model combining clinical and radiomics features from CT scans for a preoperative noninvasive evaluation of Huvos grading of neoadjuvant chemotherapy in patients with HOS.</p></div><div><h3>Methods</h3><p>183 patients from center A and 42 from center B were categorized into training and validation sets. Features derived from radiomics were obtained from unenhanced CT scans.Following dimensionality reduction, the most optimal features were selected and utilized in creating a radiomics model through logistic regression analysis. Integrating clinical features, a composite clinical radiomics model was developed, and a nomogram was constructed. Predictive performance of the model was evaluated using ROC curves and calibration curves. Additionally, decision curve analysis was conducted to assess practical utility of nomogram in clinical settings.</p></div><div><h3>Results</h3><p>LASSO LR analysis was performed, and finally, three selected image omics features were obtained.Radiomics model yielded AUC values with a good diagnostic effect for both patient sets (AUCs: 0.69 and 0.68, respectively). Clinical models (including sex, age, pre-chemotherapy ALP and LDH levels, new lung metastases within 1 year after surgery, and incidence) performed well in terms of Huvos grade prediction, with an AUC of 0.74 for training set. The AUC for independent validation set stood at 0.70. Notably, the amalgamation of radiomics and clinical features exhibited commendable predictive prowess in training set, registering an AUC of 0.78. This robust performance was subsequently validated in the independent validation set, where the AUC remained high at 0.75. Calibration curves of nomogram showed that the predictions were in good agreement with actual observations.</p></div><div><h3>Conclusion</h3><p>Combined model can be used for Huvos grading in patients with HOS after preoperative chemotherapy, which is helpful for adjuvant treatment decisions.</p></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"47 ","pages":"Article 100614"},"PeriodicalIF":3.4,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212137424000940/pdfft?md5=021e498d082af33e3f6e5119ee963bd8&pid=1-s2.0-S2212137424000940-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141325681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}